Related Experiment Videos

The Role of SGLT2 Inhibitors in Preventing the Progression of Chronic Kidney Disease in Patients with Type 2 DM: A

Aidi Alifia Putri1, Augris Shandrianti2, Iche Andriyani Liberty3

  • 1Medical Profession Program, Faculty of Medicine, Universitas Sriwijaya, Palembang.

Journal of Preventive Medicine and Hygiene
|June 8, 2026
PubMed
Abstract

Insights

SGLT-2 inhibitors significantly reduce kidney disease progression in type 2 diabetes patients. These findings support SGLT-2 inhibitors as a key treatment for renal protection, improving outcomes and potentially delaying dialysis.

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Type 2 diabetes mellitus is a leading global cause of chronic kidney disease (CKD).
  • Current treatments for diabetic CKD have limited efficacy.
  • SGLT-2 inhibitors show promise in recent clinical trials for kidney protection.

Purpose of the Study:

  • To evaluate the efficacy and safety of SGLT-2 inhibitors in delaying CKD progression.
  • To assess the impact of SGLT-2 inhibitors on reducing dialysis dependency in type 2 diabetes patients with CKD.

Main Methods:

  • Systematic literature review adhering to PRISMA 2020 protocols.
  • Searched PubMed, Cochrane Library, Sage Journals, and Europe PMC (Jan 2019-Mar 2024).
  • Keywords: "SGLT2 Inhibitor", "Prevention", "Chronic Kidney Disease", "Type 2 Diabetes"; Risk of bias assessed using RoB2.

Main Results:

  • Included 7 articles with 15,927 participants; low overall risk of bias.
  • SGLT-2 inhibitors significantly reduced renal composite outcomes versus placebo (HR 0.70, 95% CI 0.59-0.82).
  • A transient decrease in eGFR was noted, followed by stabilization.

Conclusions:

  • SGLT-2 inhibitors demonstrate efficacy in renal protection for type 2 diabetes patients with CKD.
  • Moderate certainty of evidence supports their use based on consistent RCT findings.
  • SGLT-2 inhibitors represent a valuable therapeutic option for slowing CKD progression.
Keywords:
Chronic Kidney DiseaseDiabetes Mellitus type 2SGLT2 inhibitors

Related Concept Videos

Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.